Search results
Showing 8581 to 8595 of 8927 results
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]
Discontinued Reference number: GID-TA11344
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]
Discontinued Reference number: GID-TA11467
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Discontinued Reference number: GID-TA11569
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Discontinued Reference number: GID-NG10404
Discontinued Reference number: GID-TA11401
Discontinued Reference number: GID-TA11093
Discontinued Reference number: GID-TA11433
Discontinued Reference number: GID-TA11163
Discontinued Reference number: GID-TA10568
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Learn how NICE healthtech guidance helped East London NHS Foundation Trust tackle rising demand for children's mental health services.